SSA
AVIR icon

Schonfeld Strategic Advisors’s Atea Pharmaceuticals AVIR Stock Holding History

Schonfeld Strategic Advisors’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-45,921
Closed -$164K – 2212
2025
Q4 		$164K Buy
+45,921
New +$146K ﹤0.01% 1750
2021
Q4 		– Sell
-104,378
Closed -$3.66M – 2134
2021
Q3 		$3.66M Buy
+104,378
New +$2.9M 0.04% 529

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Schonfeld Strategic Advisors's AVIR Position: Q1 2026 in Review

Schonfeld Strategic Advisors sold out of Atea Pharmaceuticals (AVIR) in Q1 2026, closing a stake of 45,921 shares — an estimated $164K sold.

Schonfeld Strategic Advisors first reported a position in AVIR in Q3 2021 and held it in 2 quarters. The position peaked at $3.66M in Q3 2021. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

  • Schonfeld Strategic Advisors reported no remaining Atea Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 45,921 Atea Pharmaceuticals shares in Q1 2026, an estimated $164K.
  • Schonfeld Strategic Advisors first reported a position in Atea Pharmaceuticals in Q3 2021 and held it in 2 quarters.
  • Schonfeld Strategic Advisors's Atea Pharmaceuticals position peaked at $3.66M in Q3 2021.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.